A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis
Primary Purpose
Multiple Sclerosis
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
testosterone
placebo gel
Sponsored by

About this trial
This is an interventional treatment trial for Multiple Sclerosis focused on measuring MS
Eligibility Criteria
Inclusion Criteria: Men, aged 18-60, with a diagnosis of multiple sclerosis by 2010 revised McDonald Criteria
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Testosterone gel
Placebo gel
Arm Description
Apply gel once a day for 96 weeks
Apply gel once a day for 96 weeks
Outcomes
Primary Outcome Measures
Whole Brain Atrophy
Secondary Outcome Measures
Full Information
NCT ID
NCT02317263
First Posted
December 3, 2014
Last Updated
August 2, 2016
Sponsor
University of California, Los Angeles
1. Study Identification
Unique Protocol Identification Number
NCT02317263
Brief Title
A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis
Study Type
Interventional
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
Withdrawn
Why Stopped
NIH did not fund the study so it never started
Study Start Date
undefined (undefined)
Primary Completion Date
January 2099 (Anticipated)
Study Completion Date
January 2099 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Los Angeles
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a multicenter, prospective, placebo-controlled, double-blind randomized Phase II clinical trial assessing the effect of testosterone treatment vs. placebo treatment for 96 weeks duration on whole brain atrophy in men with MS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
MS
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Testosterone gel
Arm Type
Active Comparator
Arm Description
Apply gel once a day for 96 weeks
Arm Title
Placebo gel
Arm Type
Placebo Comparator
Arm Description
Apply gel once a day for 96 weeks
Intervention Type
Drug
Intervention Name(s)
testosterone
Intervention Type
Drug
Intervention Name(s)
placebo gel
Primary Outcome Measure Information:
Title
Whole Brain Atrophy
Time Frame
96 weeks
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men, aged 18-60, with a diagnosis of multiple sclerosis by 2010 revised McDonald Criteria
12. IPD Sharing Statement
Learn more about this trial
A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis
We'll reach out to this number within 24 hrs